Efficacy and Safety of Toripalimab Combined With Docetaxel or Nab-paclitaxel in Patients With Advanced Gastric Cancer
Status:
Recruiting
Trial end date:
2023-05-30
Target enrollment:
Participant gender:
Summary
The single arm clinical study is to evaluate the efficacy and safety of an anti-PD-1 antibody
(Toripalimab) combined with chemotherapy (docetaxel or nab-Paclitaxel) in patients with
advanced gastric cancer who failed first-line treatment.